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BACKGROUND: Despite expectant management, preeclampsia remote

RESULTS: There was no difference in median gestational age at

from term usually results in preterm delivery. Antithrombin, which displays
antiinflammatory and anticoagulant properties, may have a therapeutic role in
treating preterm preeclampsia, a disorder characterized by endothelial
dysfunction, inflammation, and activation of the coagulation system.
OBJECTIVE: This randomized, placebo-controlled clinical trial aimed to
evaluate whether intravenous recombinant human antithrombin could
prolong gestation and therefore improve maternal and fetal outcomes.
STUDY DESIGN: We performed a double-blind, placebo-controlled
trial at 23 hospitals. Women were eligible if they had a singleton pregnancy, early-onset or superimposed preeclampsia at 23 0/7 to 30 0/7
weeks’ gestation, and planned expectant management. In addition to
standard therapy, patients were randomized to receive either recombinant
human antithrombin 250 mg loading dose followed by a continuous
infusion of 2000 mg per 24 hours or an identical saline infusion until
delivery. The primary outcome was days gained from randomization until
delivery. The secondary outcome was composite neonatal morbidity score.
A total of 120 women were randomized.

enrollment (27.3 weeks’ gestation for the recombinant human antithrombin group [range, 23.1e30.0] and 27.6 weeks’ gestation for the
placebo group [range, 23.0e30.0]; P¼.67). There were no differences in
median increase in days gained (5.0 in the recombinant human antithrombin group [range, 0e75] and 6.0 for the placebo group [range,
0e85]; P¼.95). There were no differences between groups in composite
neonatal morbidity scores or in maternal complications. No safety issues
related to recombinant human antithrombin were noted in this study,
despite the achievement of supraphysiological antithrombin
concentrations.
CONCLUSION: The administration of recombinant human antithrombin in preterm preeclampsia neither prolonged pregnancy nor
improved neonatal or maternal outcomes.

P

reterm preeclampsia (PPE) at 23 to
30 weeks’ gestation, although relatively rare in relation to the overall
incidence of preeclampsia (PE), affects
approximately 6000 to 8000 pregnancies
per year in the United States and results
in the delivery of high-risk and signiﬁcantly premature neonates who
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experience a high rate of perinatal death
and severe short- and long-term
morbidities.1e4 Expectant management
is a recommended practice in selected
patients with PPE and consists of careful
medical surveillance of the mother and
the fetus with the goal of extending
pregnancy to decrease the prematurity
complications.5,6
The current understanding of the PPE
pathophysiology points to a number of
derangements instigated by the placenta
that affect the maternal endothelium and
the kidney, including impaired vascular
endothelial growth factor signaling,
increased sensitivity to angiotensin II,
endothelial dysfunction, and inﬂammation and activation of both the coagulation system and platelets.7e9 The
pleiotropic
antiinﬂammatory
and

anticoagulant effects of antithrombin
(AT) are hypothesized to have a therapeutic role in PE.10e14 Nonclinical
studies support the hypothesis and provide evidence of the efﬁcacy of AT in
preeclamptic animal models.15,16 The
evidence of beneﬁt has been observed in
preliminary trials demonstrating that
plasma-derived AT prolonged gestational age (GA) and increased neonatal
weight at birth.17e21
The prospective randomized, doubleblind, placebo-controlled evaluation of
the Pharmacokinetics, Safety and Efﬁcacy of Recombinant Antithrombin
Versus Placebo in Preterm Preeclampsia
(PRESERVE-1) trial was designed to test
the hypothesis that patients with PPE
between 23 and 30 weeks’ gestation
randomized to receive recombinant
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AJOG at a Glance
Why was this study conducted?
This randomized, placebo-controlled clinical trial aimed to evaluate whether
intravenous recombinant human antithrombin (rhAT) could prolong gestation
and therefore improve maternal and fetal outcomes.
Key ﬁndings
Compared with placebo, the administration of rhAT in preterm preeclampsia
neither prolonged pregnancy nor improved neonatal or maternal outcomes.
What does this add to what is known?
Antithrombin use did not lead to pregnancy prolongation or improvement in
neonatal or maternal outcomes despite previous research suggesting that this
intervention could be beneﬁcial in the management of early-onset preeclampsia.

human antithrombin (rhAT) in addition
to standard of care would demonstrate a
longer interval from randomization to
delivery (latency) than patients with PPE
receiving placebo and standard of care.

Methods
Trial design and participants
We randomly assigned women aged at
least 16 years with PPE and who were at
23 0/7 to 30 0/7 weeks’ gestation with a
singleton fetus to receive either rhAT or
placebo. The primary efﬁcacy endpoint
was the difference in GA from the time of
randomization into the study to delivery
between rhAT-treated and placebotreated women. Only subjects with PPE
who were admitted to the hospital and
had a period of evaluation and stabilization, ideally <48 hours from hospitalization, were considered for this study
(Figure). This trial targeted early PPE,
diagnosed between 23 and 30 weeks’
gestation, given the signiﬁcant perinatal
morbidity and mortality associated with
prematurity. We chose weekly cutoffs
because we believed these would be the
most clinically relevant time periods. We
sought and received institutional review
board approval from 26 participating
centers. Exclusion criteria are presented
in Supplemental Box.

Randomization and study-group
assignments
Eligible women were randomly assigned
in a 1:1 ratio to either rhAT or placebo.
Randomization was blocked by study site
using variable block sizes of 2 and 4.

Throughout the trial, the randomization
scheme was generated by Medidata
(New York City, NY). Only unblinded
Medidata staff, selected contract research
organization, sponsor team, and pharmacy staff at each site had access to the
randomization scheme. Women and investigators were blinded to treatment
assignment. Unblinded pharmacy staff
prepared the study drug. The deﬁnitions
of PE and superimposed PE are presented in the Box.
Selection of recombinant human
antithrombin dosing for the trial

Mean baseline levels in previous prospective or interventional studies of AT
in PE were just below normal or low
normal (60%e82%).18e22 The effect of
several rhAT treatment scenarios on the
AT activity in pregnant women with PPE
was simulated using population pharmacokinetic modeling. Predicted cumulative AT activities were compared
with those reported for the treatment
with plasma-derived AT in PPE.18,21 The
dose of rhAT was targeted to the same
concentrations from plasma AT after
bolus administration that yielded an efﬁcacy signal in the Maki trial.18 These
target concentrations were determined
through a pharmacokinetic model of
plasma AT.
The trial drug (either rhATor placebo)
was administered through a dedicated
intravenous line. Subjects randomized to
rhAT received an initial loading dose of
250 mg rhAT for 15 minutes, immediately followed by a continuous infusion
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of 2000 mg rhAT per 24 hours for the
duration of treatment. The total daily
dose was 2250 mg on the ﬁrst day of
treatment and 2000 mg on subsequent
days. Subjects randomized to placebo
received an identical administration of
normal saline. Continuous infusion
dosing was planned to continue until a
decision to deliver or the woman reached
a GA of 34 0/7 weeks.

Follow-up visits
Posttreatment assessments of the mother
were performed at hospital discharge
and approximately 4 to 6 weeks after
delivery. Information on the neonates
was collected when they reached a
postmenstrual age of 36 weeks. If the
neonate reached 36 weeks’ postmenstrual age at <28 days after delivery,
the ﬁnal neonatal follow-up was done at
the 4- to 6-week postdelivery visit.

Outcome measures
The primary outcome was gestational
days gained, which was deﬁned as the
GA at delivery minus the GA at
randomization.
The
secondary
outcome was a 5-point composite
score based on speciﬁc fetal or
neonatal adverse outcomes associated
with
prematurity
(Supplemental
Table 1). Neonatal outcomes of speciﬁc interest were assessed from birth
to the 36 weeks’ postmenstrual age
and the 36 weeks’ postmenstrual age
visit or to the 4 to 6 weeks’ postdelivery visit (if both the 36 weeks’
postmenstrual age and the 36 weeks’
postmenstrual age visit occurred <28
days after delivery). Maternal outcomes of speciﬁc interest are presented in Supplemental Table 2.
All investigators and their corresponding participating centers were
skilled in the evaluation and management of PPE and agreed to follow the
accepted Society for Maternal-Fetal
Medicine and American College of Obstetricians and Gynecologists (ACOG)
published guidelines for delivery. Several
of the centers were also part of the
Maternal-Fetal Medicine Units Network.
Similarly, the neonatal intensive care
units (NICUs) of the participating centers were part of the national NICU
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FIGURE

Eligibility, randomization, and assessment
1,321 Women were evaluated for eligibility
1,190 Were excluded
1,120 Did not meet eligibility criteria
438 Incorrect gesta onal age
213 No preeclampsia or superimposed
preeclampsia
126 Required Delivery
119 Were not stable
52 Not a candidate for expectant
management
45 Mul fetal pregnancy
36 Renal disease
19 Treated with heparin
16 Fetal anomaly
14 Alcohol or drug use
6 Seizure disorder
2 An phospholipid an body
syndrome
41 Other
70 Declined to par cipate
120 Underwent randomiza on

62 Were assigned to expectant management
& treatment with recombinant human
an thrombin

58 Were assigned to expectant
management & normal saline as placebo

0 lost to
follow-up

3 lost to
follow-up

62 were treated in the ITT popula on
60 in the modiﬁed ITT popula on
51 in the per protocol popula on

58 were treated in the ITT popula on
54 in the modiﬁed ITT popula on
40 in the per protocol popula on

Patients were randomized at a 1:1 ratio with recombinant antithrombin as a 250 mg loading dose followed by continuous infusion at 2000 mg per 24
hours, or an identical saline infusion. Efficacy endpoints and outcomes were based on the ITT population: all women randomized according to their
treatment assignment. Modified ITT population refers to all women in the ITT population who received study treatment. Per-protocol population refers to
all women in the ITT population with no major protocol deviations.
AT, antithrombin; ITT, intent to treat.
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.

networks, which followed commonly
accepted disease deﬁnitions and practice
guidelines.

Adverse events
Safety assessments were performed
throughout the treatment and follow-up
periods.

Statistical analysis
The Shapiro-Wilk test was used to
determine whether the data were

normally distributed. An analysis of
covariance was used to test for a difference in treatment effects between rhAT
and placebo, in terms of treatment, type
of PE (PE vs superimposed PE), and GA
at study randomization (measured in
days as a continuous variable). Continuous variables were summarized using
descriptive statistics. Categorical data
were summarized by frequencies and
percentages. For dichotomous outcomes, odds ratios were estimated based

on logistic regression models in terms of
treatment, type of PE (PE vs superimposed PE), and GA at randomization.
The sample size estimation was based on
the results of the study by Maki et al.18
We estimated that 34 women per study
group would provide a power of 90% to
detect a relative increase of 33% in the
duration of the primary outcome, that is,
days gained in GA, from 7.4 days in the
placebo group to 9.7 days in the rhAT
group. We increased the sample size to
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Definition of preeclampsia and superimposed preeclampsia
Preeclampsia was defined as:
 Gestational hypertension defined as a recorded SBP of 140 mm Hg or DBP of 90 mm Hg on 2 occasions at least 4 h apart (since the
commencement of medical intervention in any facility)
Or
 Severe gestational hypertension defined as SBP of 160 mm Hg or DBP of 110 mm Hg, confirmed with a second assessment within
a short interval (min)
And new onset of any of the following:
 Proteinuria defined as 0.3 g protein per 24 h in a 12e24 h urine collection or PCR of 0.3 mg/mg (on a random sample or any
collection period)
 Platelet count of <100,000/mL
 Serum creatinine concentrations of >1.1 mg/dL in the absence of other renal diseases
 Elevated liver transaminases to twice the upper limit of normal
 Cerebral or visual symptoms
Superimposed preeclampsia was defined as:
 The start of antihypertensive medication, increasing the dose of a currently administered antihypertensive medication or adding a
second antihypertensive medication after 20 wk of pregnancy for SBP of 160 mm Hg or DBP of 105 mm Hg in a subject who had a
history of controlled hypertension before 20 wk of pregnancy
And new onset of any of the following:
 Proteinuria defined as 0.3 g protein per 24 h in a 12e24 h urine collection or PCR ratio of 0.3 mg/mg (on a random sample or any
collection period)
 Platelet count of <100,000/mL
 Serum creatinine concentrations of >1.1 mg/dL in the absence of other renal diseases
 Elevated liver transaminases to twice the upper limit of normal
 Cerebral or visual symptoms
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.

60 women per study group to assess
safety, and we also employed an adaptive
study design to better address the secondary outcome, that is, the 5-point
composite score based on speciﬁc fetal
or neonatal outcomes, given that
contemporary robust data exist for prematurity, but not speciﬁcally for PPE.23
An interim analysis was performed
when primary efﬁcacy endpoint data
were available for the ﬁrst 60 enrolled
subjects (50%).

Results
Characteristics of the participants
From July 2014 to May 2016, 1321
women were screened and a total of 120
women were randomized to receive

either rhAT (62 women) or placebo (58
women). Demographic and baseline
clinical characteristics were similar between the 2 treatment groups (Table 1).

Delivery information
The indications for delivery, mode of
delivery, and maternal complications of
interest are presented in Table 2. There
were no signiﬁcant differences between
the 2 study groups. Neonatal assessments
immediately after delivery, including
Apgar scores and body measurements,
were comparable in the rhAT and placebo
groups. The mean birthweight was 1056.9
g (standard deviation [SD], 508.16) in the
rhAT group and 1177.4 g (SD, 572.93) in
the placebo group.
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Primary and secondary outcomes
For the primary outcome, there was no
signiﬁcant difference in the median increase in GA between treatment groups
(5.0 days [range, 0e75] in the rhAT
group and 6.0 days [range, 0e85] in the
placebo group; P¼.95). For the secondary outcome, there was no signiﬁcant difference between treatment
groups in the mean composite fetal or
neonatal outcome score. The mean
composite fetal or neonatal outcome
score was 0.7 (SD, 1.0) in the rhAT
group and 0.6 (SD, 0.9) in the placebo
group (Tables 3 and 4). There was no
difference in the median increase in
gestational days gained between the
rhAT and placebo groups when the
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Compliance and adverse events

TABLE 1

Maternal demographics and baseline clinical characteristics
Parameter

rhAT (n¼61)

Placebo (n¼58)

Mean (SD)

29.0 (6.1)

29.3 (6.7)

Median

29.0

30.0

Minimum to maximum

18e50

18e44

Mean (SD)

27.18 (1.96)

27.34 (2.06)

Median

27.29

27.57

Minimum to maximum

23.1e30.0

23.0e30.0

Age at screening (y)

GA at randomization, n (%)
23 wk (23 0/7e23 6/7)

4 (6.5)

3 (5.2)

24 wk (24 0/7e24 6/7)

5 (8.1)

6 (10.3)

25 wk (25 0/7e25 6/7)

9 (14.5)

6 (10.3)

26 wk (26 0/7e26 6/7)

8 (12.9)

7 (12.1)

27 wk (27 0/7e27 6/7)

11 (11.7)

12 (20.7)

28 wk (28 0/7e28 6/7)

11 (11.7)

5 (8.6)

29 wk (29 0/7e29 6/7)

13 (21.0)

16 (27.6)

30 wk (30 0/7e30 6/7)

1 (1.6)

3 (5.2)

Asian

2 (3.2)

1 (1.7)

African American

27 (43.5)

27 (46.6)

Native American

1 (1.6)

0 (0.0)

White

29 (46.8)

30 (51.7)

Other

3 (4.8)

0 (0.0)

Hispanic

6 (9.7)

10 (17.2)

Not Hispanic

56 (90.30)

48 (82.8)

Preeclampsia

39 (62.9)

32 (55.2)

Superimposed preeclampsia

23 (37.1)

26 (44.8)

Mean

36.92 (10.20)

35.86 (7.84)

Median

34.87

35.61

Minimum to maximum

21.3e67.8

19.7e58.3

Race, n (%)

Ethnicity, n (%)

Type of preeclampsia, n (%)

2

BMI (kg/m )

BMI, body mass index; GA, gestational age; rhAT, recombinant human antithrombin; SD, standard deviation.
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.

groups were stratiﬁed at randomization
based on the diagnosis of PE vs superimposed PE; presence or absence of
proteinuria; or presence or absence of
severe-range blood pressures (BPs).
Subgroup analyses of modiﬁed intentto-treat population (ITT), deﬁned as

Original Research

all women in the ITT population who
received any study treatment, or perprotocol population, deﬁned as patients who completed the study without
any major protocol deviations, did not
indicate signiﬁcant differences between
treatment groups.

Most women completed the study drug
treatment (82% overall), with a slightly
higher proportion of study drug
completion in the rhAT group (90%)
than the placebo group (72%). Similar
proportions of neonate subjects in each
study group completed the study (93%
overall). There were no differences in
maternal adverse events between
treatment groups. The most frequently
observed maternal treatment-emergent
adverse events (TEAEs) in both treatment groups were worsened hypertension (rhAT, 53.3%; placebo, 46.3%)
and headache (rhAT, 40.0%; placebo,
35.2%). No fetus experienced a TEAE
that the investigator considered to be
related to the study drug. There were
no fetal deaths. Among neonates, at
least 1 serious adverse event was
experienced by 53.3% of neonates in
the rhAT group and 44.4% of neonates
in the placebo group. A total of 5 neonates died, of whom 3 were in the
rhAT group and 2 were in the placebo
group. No neonate experienced a
serious adverse event or death that the
investigator considered to be related to
the study drug.
RhAT administration was not associated with an increased risk of
bleeding. The estimated blood loss
after delivery was 500 to <1000 cc for
most subjects in each group (rhAT, 43
subjects [69.4%]; placebo, 34 subjects
[59.6%]), and only 2 subjects (3.2%)
(both in the rhAT group) had an
estimated blood loss of 1500 cc.
Mean changes from the baseline for
prothrombin time and activated partial
thromboplastin time were comparable
between the rhAT and placebo groups.
No statistically signiﬁcant differences
between the treatment groups in mean
changes from the baseline in coagulation parameters were observed. Overall, there was a low rate of transfusion
(3 [4.8%] and 0 [0%]) in the rhAT and
placebo groups, respectively, which
was well within the accepted previous
published experience.

Antithrombin activity
At baseline, the 2 treatment groups had a
similar mean AT activity (%) (rhAT,
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TABLE 2

Delivery information (ITT population)
Parameter

rhAT (n¼62)

Placebo (n¼58)

Mean (SD)

28.77 (2.66)

29.64 (3.24)

Median

28.79

29.64

Minimum to maximum

24.0e34.9

23.1e40.0

Maternal

43 (69.4)

40 (69.0)

Fetal

5 (8.1)

9 (15.5)

Both

14 (22.6)

9 (15.5)

3 (4.8)

6 (10.3)

36 (58.1)

28 (48.3)

GA at time of delivery (wk)

Indications for delivery (maternal, fetal, or both), n (%)

Indications for delivery, n (%)
>34 wk gestation
Refractory hypertension despite maximal medical intervention
HELLP

1 (1.6)

0 (0.0)

Thrombocytopenia

5 (8.1)

1 (1.7)

Elevated liver enzymes

10 (16.7)

4 (7.1)

Elevated LDH

5 (8.3)

1 (1.8)

Elevated total bilirubin

0 (0.0)

0 (0.0)

Oliguria with evidence of acute renal failure

0 (0.0)

0 (0.0)

Persistent visual symptoms

0 (0.0)

2 (3.4)

Placental abruption

0 (0.0)

0 (0.0)

Oligohydramnios

2 (3.2)

2 (3.4)

IUGR below fifth percentile

1 (1.6)

0 (0.0)

Pulmonary edema

2 (3.2)

3 (5.2)

Reverse end-diastolic flow on umbilical Doppler ultrasound

2 (3.2)

1 (1.7)

Biophysical score of 4/10 on 2 occasions

0 (0.0)

1 (1.7)

Nonreassuring fetal heart rate tracing

15 (24.2)

12 (20.7)

Intractable headache unrelieved with analgesia

8 (12.9)

10 (17.2)

Intractable right upper quadrant abdominal pain or vomiting

5 (8.1)

1 (1.7)

Other

17 (27.4)

14 (24.1)

Eclamptic seizure

0 (0.0)

1 (1.7)

HELLP

1 (1.6)

0 (0.0)

Oliguria with evidence of acute renal failure

0 (0.0)

0 (0.0)

Pulmonary edema

2 (3.2)

3 (5.2)

Stroke

0 (0.0)

0 (0.0)

Vaginal delivery

5 (8.1)

11 (19.0)

Cesarean delivery

57 (91.9)

47 (81.0)

3 (4.8)

0 (0.0)

Maternal complications of interest

Mode of delivery, n (%)

Blood transfusion required within 24 h after delivery, n (%)

GA, gestational age; HELLP, hemolysis, elevated liver enzymes, and low platelet; ITT, intent to treat; IUGR, intrauterine growth restriction; LDH, lactate dehydrogenase; rhAT, recombinant human
antithrombin; SD, standard deviation.
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.
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TABLE 3

Secondary outcome: composite endpoint of fetal and neonatal outcomes
(ITT)
Parameter
population
statistic

rhAT (n¼60)

Placebo
(n¼56)

Difference
(rhATplacebo)

Adjusted
difference,
95% CI
(rhATplacebo)

P value

Composite endpoint of fetal and neonatal outcomes
Mean (SD)

0.7 (1.0)

0.6 (0.9)

0.1

0.0 (0.3 to 0.4)

.7824

Median

0.0

0.0

—

—

—

Minimum to
maximum

0e4

0e4

—

—

—

Fetal and neonatal events include BPD, IVH (grade 3), cystic PVL, ROP (stage 3), late sepsis, and NEC (Bell’s stage 2).
Scores: 0, no events, no mortality; 1, 1 event, no mortality; 2, 2 events, no mortality; 3, 3 or more events, no mortality; 4, death.
The secondary efficacy endpoint is a composite endpoint of specific fetal and neonatal outcomes consisting of BPD, IVH, PVL,
ROP, late sepsis, NEC, and mortality (fetal and neonatal). Multiple imputation methods were used for the imputation of any
missing data for the secondary efficacy endpoint. The regression model included treatment, type of PE (PE vs superimposed PE),
and GA at randomization (measured in days as a continuous variable). For subjects for whom both 36-week PMA and the 36week PMA visit occurred in <28 days after delivery, the secondary outcome endpoint includes events occurring during the 4e6
week postdelivery visit.
BPD, bronchopulmonary dysplasia; CI, confidence interval; GA, gestational age; ITT, intent to treat; IVH, intraventricular
hemorrhage; NEC, necrotizing enterocolitis; PE, preeclampsia; PMA, postmenstrual age; PVL, periventricular leukomalacia;
rhAT, recombinant human antithrombin; ROP, retinopathy of prematurity; SD, standard deviation.
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.

94.70 [SD, 14.60]; placebo, 93.05 [SD,
14.29]). Maximum ATactivity (%) in the
rhAT group was 291.7 (observed at day
8). A total of 15 patients had baseline AT
levels below 80% (8 in the rhAT group
and 7 in the placebo group), and their
results were consistent with the overall
results of the study. The mean ATactivity
in umbilical cord blood was 28.25 (SD,
8.63) in the rhAT group and 31.44 (SD,
14.46) in placebo group subjects, indicating that rhAT did not cross the
placenta.

Comment
The key ﬁndings of our study are as
follows: (1) rhAT administration to
women with singleton gestation diagnosed as having PPE between 23 and 30
weeks’ gestation did not extend their
pregnancy more than the expectant
management alone; (2) the median increase in GA was 5.0 days in the rhAT
group and 6.0 days in the placebo group;
(3) rhATadministration did not improve
individual or composite fetal or neonatal
outcomes; and (4) there were no safety
issues related to rhAT administration in
the setting of PPE, despite supraphysiological AT levels and prolonged
administration.

In our study, the rhAT and placebo
groups were generally well balanced at
baseline. The treatment groups had a
similarly high mean body mass index
(BMI) at screening (36e37 kg/m2). We
do acknowledge that there were some
potentially important differences in the
respective treatment group proﬁles at
baseline. For example, there were differences between the groups in obstetrical history. The percentage of ﬁrst-time
pregnancies was higher in the rhAT
group (37%) than the placebo group
(22%), with an even greater difference in
the number of subjects who had no
previous live births (rhAT, 60%; placebo,
28%), corresponding with higher rates
of previous neonatal morbidity, miscarriage, and abortion in the rhAT group.
The mean number of previous live births
in the placebo group was double than
that of the rhAT group (rhAT, 0.7; placebo, 1.4). Of the subjects who did have
previous deliveries, the mean minimum
GA for previous deliveries was 4 weeks
less in the rhAT group in comparison
with the placebo group (31 weeks vs 35
weeks). The intrauterine growth restriction at baseline was more frequent
in the rhAT group than the placebo
group (27% vs 19%, respectively). These
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data suggest a more severe obstetrical
history among subjects from the rhAT
group. In contrast, the percentage of
subjects who had previously experienced
PE was lower in the rhAT group than the
placebo group (28% and 40%, respectively). Although the diagnostic criteria
used for subjects with superimposed PE
were comparable between groups,
women in the rhAT group who were
diagnosed as having PE may have been in
a more severe condition at the time of
diagnosis than subjects in the placebo
group. In the superimposed PE subgroup, nearly twice as many patients in
the rhAT group were diagnosed as having the criteria of severe gestational hypertension than the placebo group (17 vs
9, respectively). In addition, the mean
systolic and diastolic BP used for diagnosis was higher in the rhAT group
(rhAT, 165.2/97.5 mm Hg; placebo,
159.1/95.7 mm Hg). Ten patients in the
rhAT group developed thrombocytopenia or hemolysis, elevated liver enzymes, and low platelet (HELLP)
syndrome compared with 2 patients in
the placebo group. Overall, these few
differences between the rhAT and placebo are unlikely to account for the lack
of efﬁcacy of rhAT in prolonging gestation in this trial. We were unable to
detect any beneﬁt of rhAT administration in any PE subgroup.
The efﬁcacy results in our trial are not
consistent with earlier results from the
Maki study in Japan18 that showed a
signiﬁcant and clinically relevant prolongation of pregnancy of approximately
1 week with ATreplacement (16.8 days vs
10.2 days for the placebo group). The
Maki study and the current study population differed in background characteristics, most notably in GA difference,
racial composition, and BMI, which
were substantially higher in our study. In
the Maki study, the mean GA in the ATtreated and placebo groups at randomization was 31.8 (SD, 3.2) and 31.7 (SD,
2.7) weeks, respectively, which was
nearly 1 month later than that in our
study population. In the Maki study,18
patients diagnosed as having PE between 24 to 35 weeks’ gestation were
included if the patients experienced a
systolic BP of 160 mm Hg and/or
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diastolic BP of 110 mm Hg and/or
proteinuria of 2 g/L of protein in a 24hour urine collection and a Gestosis Index of  6 on 2 occasions at least 6 hours
apart despite bed rest. Patients with
chronic hypertension, renal disease,
diabetes mellitus, systemic lupus erythematosus, multiple pregnancy, and
other severe medical conditions were
excluded. Patients with AT deﬁciency
were also excluded. Compared with our
study, Maki et al18 included patients at a
later GA and required higher BPs.
Other supportive evidence for the use
of AT replacement in PPE came from the
study of Paternoster et al21 who found
that higher doses of AT replacement in
patients with severe PE between 24 and
33 weeks’ gestation were associated with
greater prolongation of pregnancy. In
the Paternoster study,21 subjects diagnosed as having PE between 24 to 33
weeks were included in the study on the
basis of the following criteria: diastolic
arterial pressure of >90 mm Hg and
systolic arterial pressure of >140 mm Hg
on more than 3 occasions, proteinuria
(in a 24-hour urine sample) of >0.3 g/L,
and AT of 75%. Patients with chronic
hypertension, renal disease, diabetes
mellitus, systemic lupus erythematosus,
multiple pregnancies, and other severe
medical conditions were excluded.
Compared with our study, Paternoster
et al21 included patients at a later GA and
required decreased AT activity for
enrollment.
Toward the end of our study, D’Angelo et al24 reported on a multicenter
randomized trial with negative results,
using high-dose AT replacement in PPE.
These investigators had planned to enroll
240 patients from 13 centers but only
enrolled 38 patients; the sponsor terminated the trial because of poor enrollment. In the D’Angelo study,24 patients
diagnosed as having PE at <30 weeks’
gestation were included. The criteria for
the diagnosis of PE were diastolic BP
repeatedly at >90 mm Hg plus a daily
proteinuria of 0.3 g. The exclusion
criteria were conditions requiring immediate delivery. Compared with our
study, D’Angelo et al24 included patients
at a similar GA and did not require
decreased AT activity for enrollment,

which was similar to our study. In our
study, we enrolled singleton patients
with PE diagnosed between 23 to 30
weeks’ gestation who were being expectantly managed. We included patients
with chronic hypertension, and AT levels
were not a criterion for entry into the
study. We excluded patients with multiple gestation.
We found that baseline AT activity
levels were higher than expected,
consistent with the ﬁndings of the
D’Angelo study and at odds with the
Maki study and the initial study
describing AT activity in PE.25 D’Angelo
et al24 found normal mean (SD) AT activity levels at baseline in most randomized patients with PE (88%16%
and 85%85% for the patients receiving
AT and placebo, respectively). Peak AT
activity levels in our study were consistent with the Maki study, which found a
peak plasma AT activity of 200%
immediately after the AT infusion, and
the D’Angelo study (244%). Hence,
insufﬁcient dosing is unlikely to account
for our negative efﬁcacy results and the
study by D’Angelo. Moreover, our
continuous daily infusion of rhAT would
also have mitigated against AT elimination losses previously reported in patients with PE.19
Another consideration that might
explain our negative ﬁndings is the lack
of homogeneity of our patient population. Just before the study started, the
ACOG released new diagnostic criteria
for PE.6 We incorporated the new
criteria into our current protocol. Proteinuria was no longer required for the
diagnosis of PE. The median prolongation of pregnancy in the subgroup of
patients without proteinuria at baseline
was 24 days in contrast to 5 days in the
group that had proteinuria.
Another possibility for the lack of effect in our study may be related to the
timing of study drug administration in
relation to the clinical status of the patient and when the patient was admitted
to the hospital. It is possible that the
delay in the timing of study drug
administration affected the ability to
detect a treatment difference. Owing to
enrollment challenges, the GA was
extended to 30 weeks. Consequently,
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the overall rate of neonatal morbidity
was quite low, and the mean composite
score was <1.

Limitations
Although 23 sites participated in the
trial, only 7 (30%) enrolled more than 5
patients, which attests to the challenge of
an interventional trial in a pregnant
population with a relatively rare disease.
Initial enrollment into the trial was slow,
so the upper limit of GA inclusion
criteria was extended from 28 to 30
weeks in an effort to accelerate study
enrollment. However, this change
contributed to a very low neonatal
composite score. It would have been
difﬁcult to show a neonatal beneﬁt even
if rhATextended pregnancy signiﬁcantly.
The diagnosis of PE was based on the
deﬁnition of PE in place at the time,
which allows for some patients to be
diagnosed as having PE based on subjective criteria (eg, severe headache)
along with BP criteria. Another potentially challenging diagnostic criterion
relates to the BP criteria for superimposed PE. The guidelines suggested
that “a sudden increase in blood pressure
that was previously well controlled”
satisﬁes the PE criteria,6 which is
imprecise. We insisted on an increase in
BP requiring either a start of an antihypertensive agent, increasing the dose of a
current agent, or adding a second agent,
which increased the likelihood of
correctly identifying patients with
superimposed PE.

Strengths
The PRESERVE-1 trial represents the
largest, most comprehensive study of
PPE ever completed in the United States.
The trial was completed in <2 years,
which is remarkable considering the
rarity of the patient population and the
operational complexity of the trial
design. The study was adequately powered to address the primary outcome. An
adaptive study design enabled a sample
size reestimation. Only principal investigators and centers comfortable with
expectant management participated in
the trial. The study inclusion and
exclusion criteria were based on the
current guidelines at the time.5,6 The
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TABLE 4

Fetal or neonatal outcomes of specific interest
Parameter

rhAT (n¼62),
n (%)

Placebo (n¼58),
n (%)

Fetal death (including stillbirth)

0 (0.0)

0 (0.0)

Difference (%)
(rhATplacebo)

Odds ratio (95% CI)
(rhATplacebo)

P value

0.0

N/A

—

Neonatal death

3 (4.8)

2 (3.4)

1.4

1.541 (0.197e12.033)

.6799

SGA of <10%

12 (19.4)

9 (15.5)

3.9

1.384 (0.514e3.726)

.5201

RDS

59 (95.2)

51 (87.9)

7.3

2.724 (0.665e11.154)

.1635

BPD

22 (35.5)

20 (34.5)

1.0

0.989 (0.456e2.142)

.9774

ROP stage 3

0 (0.0)

0 (0.0)

0.0

N/A

—

NEC (Bell’s grade 2)

1 (1.6)

2 (3.4)

1.8

0.493 (0.043e5.642)

.5692

IVH 3

3 (4.8)

1 (1.7)

3.1

2.606 (0.257e26.460)

.4179

Cystic PVL

2 (3.2)

1 (1.7)

1.5

1.250 (0.101e15.475)

.8618

Early sepsis (positive blood culture not
regarded as contaminant within 72 h of
delivery)

0 (0.0)

0 (0.0)

0.0

N/A

Late sepsis (positive blood culture not
regarded as contaminant >72 h of delivery)

2 (3.2)

4 (6.9)

3.7

0.540 (0.060e3.232)

.5001

Meningitis

0 (0.0)

1 (1.7)

1.7

N/A

.9441

Avoidance of neonatal morbidity (BPD, IVH
grade 3, cystic PVL, ROP stage 3, late
sepsis, and NEC Bell’s grade 2) and of
fetal or neonatal mortality

6 (58.1)

33 (56.9)

1.114 (0.521e2.382)

.7813

1.2

—

For subjects who did not complete the study, data up to their discontinuation were used. The odds ratio and 95% CI and the P value are for the treatment effect from a logistic regression model in terms
of treatment, type of preeclampsia (preeclampsia vs superimposed preeclampsia), and GA at randomization.
BPD, bronchopulmonary dysplasia; CI, confidence interval; IVH, intraventricular hemorrhage; N/A, not available; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; RDS, respiratory
distress syndrome; rhAT, recombinant human antithrombin; ROP, retinopathy of prematurity; SGA, small for gestational age.
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.

decision to deliver was made uniquely by
a maternal-fetal medicine specialist. The
assumptions underlying the pharmacokinetic modeling were proven to be accurate. This trial establishes the safety of
rhAT in PPE even with supraphysiological levels of rhAT.

Conclusion
The administration of rhAT to women
with singleton pregnancy diagnosed as
having early-onset PE between 23 and 30
weeks’ gestation was not associated with
pregnancy prolongation and improvement in maternal or neonatal outcomes.
rhAT is safe for pregnant women with
PPE and their fetus or neonates.
Given the conﬂicting results regarding
AT supplementation in PPE, additional
studies are indicated to determine its
potential beneﬁt in this vulnerable patient population. Nulliparous women

with singleton gestation, without preexisting chronic hypertension or other
medical conditions, diagnosed as having
PE between 23 and 28 weeks with AT
activity levels of <80% would constitute
the ideal patient population in a randomized clinical trial to determine
whether rhAT antenatal administration
will prolong gestation.
n
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SUPPLEMENTAL TABLE 1

A priori fetal or neonatal outcomes of specific interest
Perinatal complication

Definition

Fetal death

Includes stillbirth

Neonatal death

Death from day 0 (not stillbirth) to the last study
assessment

All death

Fetal and neonatal death

SGA

Below the tenth percentile weight by gender from
Fenton et al26

RDS

Clinical features of RDS and oxygen or respiratory
support for 6 h of the first 24 h of life

BPD

Oxygen requirement at 36 wk postmenstrual age

ROP

Severe (stage 3) retinopathy of prematurity

NEC

Bell’s stage 2

IVH

Cranial ultrasound, CT, or MRI evidence for IVH grade
3

Cystic PVL

Cranial ultrasound, CT, or MRI evidence for cystic PVL

Early sepsis

Early sepsis (positive blood culture not regarded as
contaminant), within 72 h of delivery

Late sepsis

Late sepsis (positive blood culture not regarded as
contaminant) more than 72 h after delivery

Meningitis

Positive culture of cerebrospinal fluid

BPD, bronchopulmonary dysplasia; CT, computed tomography; IVH, intraventricular hemorrhage; MRI, magnetic resonance imaging; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia;
RDS, respiratory distress syndrome; ROP, retinopathy of prematurity; SGA, small for gestational age.
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.
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SUPPLEMENTAL TABLE 2

A priori maternal outcomes of specific interest
Maternal complication

Definition

Maternal death

Documented death of any cause during the trial up to 28 d after delivery

Eclamptic seizure

Presence of new-onset grand mal seizures in a woman with preeclampsia,
without evidence for other etiology (eg, bradycardia, tachycardia, hypotension,
expected or unexpected drug effect)

Myocardial infarction

Detection of a rise and/or fall of cardiac biomarker values (cardiac troponin) with
at least 1 value above the 99th percentile upper reference limit and with at least
one of the following:
 Symptoms of ischemia
 New or presumed new significant ST-segment T-wave (ST-T) changes or new
left bundle branch block
 Development of pathologic Q waves in the ECG
 Imaging evidence of new loss of viable myocardium or new regional wall
motion abnormality
 Identification of an intracoronary thrombus by angiography or autopsy

CVA

Acute onset of a focal neurologic deficit, with CT or MRI evidence for hemorrhagic
CVA or cerebral infarction (brain or retinal cell death caused by prolonged
ischemia)

Transient ischemic
attack

A brief episode (usually less than 1 or 2 h) of neurologic dysfunction caused by
focal brain or retinal ischemia without evidence of acute infarction (as
determined by CT or MRI)

Progressive renal
insufficiency

 Serum creatinine of >1.1 mg/dL

Thrombocytopenia
(without HELLP)

 Platelet count of <100,000/mL

HELLP

A combination of:
 AST of 70 IU/L
 Platelet count of <100,000/mL
 Evidence of hemolysis on blood film plus either LDH of 600 IU/mL or total
bilirubin of 1.2 mg/dL

DIC

Overt DIC is defined as a score of 5 derived from scoring the following
parameters:
 Platelet count of 100/mm3 (0), 50/mm3 but <100/mm3 (1), <50/mm3 (2)
 Elevated fibrin-related marker such as soluble fibrin monomer or fibrin
degradation products with no increase (0), moderate increase (2), strong
increase (3)
 Prolonged PT of 3 s (0), >3 but <6 s (1), and 6 s (2)
 Fibrinogen level of 1.0 g/L (0) and <1.0 g/L (3)

Pulmonary edema

Clinical symptoms of pulmonary edema, confirmed by chest x-ray examination

Placental abruption

Vaginal bleeding and uterine pain or tenderness accompanied by documented
fetal distress or uterine hypertonicity

Severe intra- and
postpartum hemorrhage

Estimated blood loss of 1500 mL within 24 h after delivery

VTE including DVT and
pulmonary embolism

Clinically symptomatic VTE (eg, breathlessness, hemoptysis, leg pain, and
swelling) with confirmation by appropriate diagnostic tools (eg, venography,
Doppler ultrasound, ventilation or perfusion scan, MRI)

AST, aspartate aminotransferase; CT, computed tomography; CVA, cerebrovascular accident; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; ECG, electrocardiogram;
HELLP, hemolysis, elevated liver enzymes, and low platelet; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; PT, prothrombin time; VTE, venous thromboembolism.
Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.
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SUPPLEMENTAL BOX

Exclusion criteria
Criteria requiring immediate delivery of the fetus before randomization:
 Refractory hypertension despite maximal medical intervention of systolic blood pressure of 160 mm Hg or diastolic blood pressure of
110 mm Hg
 Thrombocytopenia (platelets <100,000/mL) with or without HELLP syndrome, defined as:
o AST of 70 units/L
o Platelet count of <100,000/mL
o Evidence of hemolysis on blood film plus either LDH of 600 IU/mL or total bilirubin of 1.2 mg/dL; oliguria (500 mL/24 h)
o Evidence of progressive renal insufficiency
 Serum creatinine concentration of >1.1 mg/dL
 Persistent visual disturbances
 Placental abruption
 Pulmonary edema
 Nonreassuring fetal heart rate tracing
 Intractable headache unrelieved with analgesia
 Intractable right upper quadrant abdominal pain or vomiting
 If umbilical Doppler ultrasound had been performed, the presence of an abnormal umbilical artery Doppler as defined by persistent,
absent, or reverse end-diastolic flow
 Biophysical score of 4/10 on 2 occasions
 Oligohydramnios (deepest vertical pocket of <22 cm on ultrasound)
 Other maternal or fetal conditions that would preclude expectant management
Other exclusion criteria:





Known lethal or major fetal anomaly
Recent (within 12 mo) history of maternal alcoholism or drug dependence
Diagnosis of epilepsy
Need for chronic therapy with NSAIDs including selective Cox-2 inhibitors, or unwilling to abstain from the use of NSAIDs during the
study treatment period (low-dose aspirin of 81 mg/d or less was allowed)
 Received within 72 h or had requirement for heparin
 Low-molecular-weight heparin such as enoxaparin or dalteparin
 Fondaparinux
 Antiplatelet agents such as clopidogrel, prasugrel, or high-dose aspirin (>81 mg/d)
 DTIs such as dabigatran
 Preexisting renal disease, documented prepregnancy or in pregnancy before 20 wk gestation (before the diagnosis of preeclampsia), or
24 h urine of 0.3 g/24 h, documented in pregnancy, before 20 wk gestation, or 2þ dipstick or 0.3 PCR, documented in pregnancy at
the last available test before 20 wk gestation
o In the case of conflicting results between dipstick, PCR, and timed urine collection to work up an episode of proteinuria, the timed
urine collection result would supersede other results.
 Multifetal pregnancy
 History of antiphospholipid antibody syndrome
 Known hypersensitivity to goat and goat milk proteins
 Participation in another interventional clinical trial of an investigational, unapproved therapy (drug, biologic, device) within 30 d of
consent
AST, aspartate aminotransferase; Cox, cyclooxygenase; DTI, direct thrombin inhibitor; HELLP, hemolysis, elevated liver enzymes, and low platelet; LDH, lactate dehydrogenase;
NSAID, nonsteroidal antiinﬂammatory drug; PCR, polymerase chain reaction. Paidas et al. Recombinant AT vs placebo in preterm preeclampsia. Am J Obstet Gynecol 2020.
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